Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In a biologics company planning a biosimilar pathway, advisory-committee question list that exposes a weak secondary endpoint is the evidence after a payer demanding RWE the protocol cannot generate. Clinical-development physician has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy close using advisory-committee question list that exposes a weak secondary endpoint.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. Advisory-committee question list that exposes a weak secondary endpoint reads as Proceed under protocol once a payer demanding RWE the protocol cannot generate is lined up to the same Pharma & Life Sciences population. 2. Advisory-committee question list that exposes a weak secondary endpoint is closer to Pause the pathway after a payer demanding RWE the protocol cannot generate; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in advisory-committee question list that exposes a weak secondary endpoint for clinical-development physician in a biologics company planning a biosimilar pathway. 4. Advisory-committee question list that exposes a weak secondary endpoint is missing the fact clinical-development physician needs after a payer demanding RWE the protocol cannot generate; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a payer demanding RWE the protocol cannot generate. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (advisory-committee question list that exposes a weak secondary endpoint after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for clinical-development physician in a biologics company planning a biosimilar pathway.